Peptide therapy medical history review: what clinicians should check before prescribing

A clinician should review the patient goal, diagnoses, medication and supplement list, allergies, pregnancy status when relevant, prior reactions, labs or vitals when needed, product-specific contraindications, pharmacy source, costs, and follow-up plan before making a prescription decision.

Yes. A responsible clinician may decline, delay, change, or redirect treatment if the history suggests higher risk, unclear diagnosis, missing labs, medication interactions, pregnancy concerns, unsafe pharmacy sourcing, or a better fit for primary care, dermatology, cardiology, endocrinology, or urgent evaluation.

Not all visits require the same labs, but labs may be important for certain goals, products, symptoms, or refill decisions. GLP-1 weight-loss care, growth-hormone-axis discussions, fatigue symptoms, metabolic risk, or complex medication histories often need more context than a simple questionnaire.

Red flags include no clinician review, no prescription requirement for human-use products, research-use peptides sold as treatment, hidden pharmacy sourcing, generic dose charts, guaranteed results, no side-effect instructions, and automatic refills without reassessing response or tolerability.

No. Compounded medications can be prescribed for individual patients when clinically appropriate and legally available, but compounded finished drug products are not FDA-approved in the same way as branded medications. The clinician and pharmacy source should be transparent about that distinction.

Yes, especially if you have chronic conditions, abnormal labs, side effects, surgery plans, pregnancy questions, or multiple medications. Sharing the active ingredient, pharmacy label, dose instructions from the prescriber, side effects, and lab results helps reduce duplicate or conflicting care.